<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690348</url>
  </required_header>
  <id_info>
    <org_study_id>20-542</org_study_id>
    <nct_id>NCT04690348</nct_id>
  </id_info>
  <brief_title>Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study</brief_title>
  <official_title>Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GT Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Cs-131 brachytherapy is effective in people with&#xD;
      recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s).&#xD;
      The researchers would like to see whether Cs-131 prevents brain tumors from growing back&#xD;
      after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain&#xD;
      surgery) with the usual approach of brain surgery without brachytherapy. The researchers will&#xD;
      compare both the effectiveness and safety of the two approaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized phase II single-institution trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patient will be blinded to their treatment until postoperatively.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>freedom from local progression</measure>
    <time_frame>9 months following surgery</time_frame>
    <description>With a contrast enhanced brain MRI scan. Treatment response will be determined based on the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>wound complications</measure>
    <time_frame>3 months</time_frame>
    <description>Physical examination including wound examination will be performed, and wound complications (including dehiscence, superficial/deep infection, CSF leak) will be recorded by the evaluating clinicians.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Recurrent Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Resection without brachytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo craniotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resection plus brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Craniotomy</intervention_name>
    <description>Craniotomy</description>
    <arm_group_label>Resection plus brachytherapy</arm_group_label>
    <arm_group_label>Resection without brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cesium-131 brachytherapy</intervention_name>
    <description>Intracavitary Cesium-131 brachytherapy</description>
    <arm_group_label>Resection plus brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients ≥ 18 years of age who are capable of giving consent&#xD;
&#xD;
          -  Undergoing elective craniotomy for resection of a previously-irradiated brain&#xD;
             metastasis with suspicion for viable disease at the time of consent, and anticipated&#xD;
             achievement of gross-total or near-total (&gt;/=95%) resection&#xD;
&#xD;
          -  Karnofsky Performance Status score (KPS) of ≥70&#xD;
&#xD;
          -  Ability to undergo brain MRI with gadolinium&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to tolerate MRI or CT imaging&#xD;
&#xD;
          -  Pregnancy (patients must have a negative pregnancy test within 30 days of the&#xD;
             operation)&#xD;
&#xD;
          -  Women must agree to not breastfeed for at least 12 weeks after the procedure&#xD;
             (lactating and discarding in that interval allowable)&#xD;
&#xD;
          -  Diagnosis of leptomeningeal carcinomatosis or &gt;5 additional active or untreated CNS&#xD;
             lesions for a total of &gt;6 active lesions&#xD;
&#xD;
          -  Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2&#xD;
&#xD;
          -  Apposition of tumor margin to brainstem or optic apparatus&#xD;
&#xD;
          -  Previous infection within the operative field, current active systemic infection&#xD;
             requiring systemic therapy, or immunodeficiency&#xD;
&#xD;
          -  Absence of native cranium or inability to reconstruct with native cranial bone flap&#xD;
&#xD;
          -  Urgent surgery required prior to availability of brachytherapy&#xD;
&#xD;
        Intraoperative Exclusion Criterion:&#xD;
&#xD;
          -  Patients will be excluded if intraoperative pathology is not consistent with &gt;/=5%&#xD;
             viable metastatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Moss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelson Moss, MD</last_name>
    <phone>212-639-7075</phone>
    <email>mossn@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathryn Beal, MD</last_name>
    <phone>212-639-5159</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge (Consent Only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Moss, MD</last_name>
      <phone>212-639-7075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Consent Only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Moss, MD</last_name>
      <phone>212-639-7075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent Only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Moss, MD</last_name>
      <phone>212-639-7075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Moss, MD</last_name>
      <phone>212-639-7075</phone>
    </contact>
    <contact_backup>
      <last_name>Kathryn Beal, MD</last_name>
      <phone>212-639-5159</phone>
    </contact_backup>
    <investigator>
      <last_name>Nelson Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Moss, MD</last_name>
      <phone>212-639-7075</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cs-131 Brachytherapy</keyword>
  <keyword>Brain Metastasis</keyword>
  <keyword>20-542</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

